Rubicon Research Limited’s board has approved the formulation and adoption of the Employees Stock Option Scheme 2026. The scheme authorizes the grant of stock options aggregating 24,84,415, corresponding to an equal number of equity shares of INR 1 each, to eligible employees of the company and its subsidiaries. This approval, granted on May 29, 2026, is subject to the approval of shareholders and other regulatory or statutory approvals.

The new scheme is in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The total pool of options includes 6,72,162 balance options available under the existing Scheme 2022. The board has the authority to grant these options in one or more tranches.

The exercise price of the stock options will not be less than the face value of the equity shares of the company. Specific details regarding the time within which the options may be exercised and other significant terms will be disclosed at the time of seeking shareholder approval.

Key Details of ESOS 2026

The board meeting commenced at 02:30 PM IST and concluded at 4:10 PM IST on May 29, 2026. Deepashree Tanksale, Company Secretary, confirmed the outcome in the regulatory filing.

Rubicon Research Limited has completed the acquisition of an 85% stake in Arinna Lifesciences Limited on April 30, 2026. The transaction was executed as a secondary acquisition under the terms agreed in the Share Purchase Agreement, as intimated to the stock exchanges. This development follows the company's earlier communication dated April 15, 2026.

Transaction Details

The acquisition involves the purchase of securities representing an 85% stake in Arinna Lifesciences Limited. The completion of this transaction marks a significant expansion for Rubicon Research Limited in the lifesciences sector. The deal was structured as a secondary acquisition, indicating the purchase of existing shares rather than new issuance.

Subsidiary Status

Following the completion of the acquisition, Arinna Lifesciences Limited has become a subsidiary of Rubicon Research Limited. This change in ownership structure will enable the company to consolidate the operations and financials of Arinna Lifesciences Limited going forward.

Regulatory Compliance

The intimation regarding the completion of this acquisition was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was addressed to both BSE Limited and National Stock Exchange of India Limited, with Rubicon Research Limited listed under scrip code 544578 on BSE and symbol RUBICON on NSE.